The research, led by Zhuohua Wen, Xiheng Chen, and Xin Tong of Southern Medical University in Guangzhou together with colleagues at several major Chinese hospitals, is a nested analysis within a prospective multicenter cohort known as the SESIA study. Rather than a small retrospective chart review, the investigators drew on a carefully maintained registry of patients undergoing flow diverter implantation for unruptured aneurysms, allowing them to examine outcomes with a degree of rigor rarely achieved in this field. Using propensity-score matching with exact matching on aneurysm location, the team assembled 1327 patients, of whom 360 received glucocorticoids and 967 did not. This statistical technique attempts to balance the two groups on every measurable characteristic, including age, aneurysm size, aneurysm location, and procedural details, so that the only meaningful difference between them is the exposure being studied.

The glucocorticoid regimen itself was strikingly simple. Patients received intravenous glucocorticoids initiated within two hours of the flow diverter procedure and continued for at least two days afterward. The doses were deliberately low, far below the levels typically used to suppress severe autoimmune disease, reflecting the idea that only a modest dampening of the inflammatory cascade was needed to protect the vessel wall during the most vulnerable period after stent deployment. This is not a new drug, not an experimental molecule, and not an expensive biologic; glucocorticoids such as methylprednisolone have been mainstays of medicine for decades and cost only a few dollars per course, making the findings immediately relevant to hospitals in every corner of the world.

The results are dramatic. In the hospital, 6.9 percent of patients who received glucocorticoids experienced a cerebrovascular event, compared with 13.1 percent of those who did not, an adjusted odds ratio of 0.53. When the investigators focused on major cerebrovascular events, the most serious complications such as disabling strokes, the difference was even more pronounced: 4.7 percent in the glucocorticoid group versus 12.4 percent in the control group, an adjusted odds ratio of 0.37, meaning the treatment was associated with nearly a two-thirds reduction in the odds of these severe outcomes. In practical terms, for every hundred patients treated with a flow diverter, the addition of a short glucocorticoid course could prevent roughly seven major cerebrovascular events that would otherwise occur during the hospital stay.

The benefits did not stop when patients left the hospital. Over a median follow-up of two years, the glucocorticoid group experienced fewer new-onset major cerebrovascular events, 3.6 percent versus 8.7 percent, with an adjusted hazard ratio of 0.41. The investigators also examined the stents themselves using imaging and found significantly less in-stent stenosis, the narrowing that occurs when scar tissue and inflammation build up inside the device and restrict blood flow through the parent artery. In-stent stenosis occurred in 7.9 percent of glucocorticoid-treated patients compared with 13.2 percent of controls, an adjusted odds ratio of 0.55. This finding is particularly important because in-stent stenosis is not merely a technical concern; it can compromise the long-term patency of the vessel, reduce blood flow to downstream brain regions, and in some cases necessitate additional procedures or antiplatelet therapy adjustments.

The biological rationale for these findings is grounded in the inflammatory response that follows endovascular device implantation. When a flow diverter is deployed, the metallic mesh comes into contact with the vessel wall, activating platelets, complement proteins, and leukocytes. Inflammatory cells infiltrate the vessel wall, releasing cytokines and proteases that promote both thrombus formation on the device surface and smooth muscle cell proliferation within the arterial wall. Glucocorticoids bind to intracellular receptors that translocate to the nucleus and suppress the transcription of pro-inflammatory genes, including those encoding tumor necrosis factor and interleukins, while promoting the resolution of inflammation through the upregulation of anti-inflammatory mediators such as annexin A1. By tempering this cascade during the critical perioperative window, a short course of low-dose steroids may prevent the initial inflammatory trigger from escalating into clinically significant thrombosis or stenosis.

The investigators were careful to test the robustness of their findings. Sensitivity analyses in unmatched patients, meaning the full cohort without propensity-score balancing, confirmed the same direction of effect, suggesting that the results are not an artifact of the matching procedure. The team also used adjusted models that accounted for residual confounding, and the findings remained consistent across multiple statistical approaches. Still, the authors are appropriately cautious in their interpretation. This is an observational analysis, not a randomized controlled trial, and it is possible that unmeasured differences between patients who received glucocorticoids and those who did not could have influenced the outcomes. The appropriate conclusion, as the authors state, is that perioperative glucocorticoid regimens warrant testing in randomized trials, not that every flow diverter patient should immediately receive steroids.

Nevertheless, the implications are significant. Flow diverter therapy has become the standard of care for many unruptured intracranial aneurysms, and the procedure is performed in tens of thousands of patients worldwide each year. Cerebrovascular complications after flow diverter implantation remain a major source of morbidity, and current strategies rely primarily on dual antiplatelet therapy with aspirin and a P2Y12 inhibitor such as clopidogrel or ticagrelor. Antiplatelet drugs address clot formation but do nothing to suppress the inflammatory response that drives vessel wall thickening and in-stent stenosis. Glucocorticoids, by contrast, target the inflammatory arm of the response, potentially complementing antiplatelet therapy in a way that no existing drug currently does. If randomized trials confirm these findings, a short course of low-dose intravenous steroids could become a routine adjunct to flow diverter procedures, adding only a few dollars to the cost of a treatment that already costs tens of thousands of dollars.

The study also highlights a broader lesson for modern medicine. Some of the most impactful advances in patient care come not from novel molecules but from rethinking how existing, inexpensive drugs are used in new clinical contexts. Glucocorticoids have been available since the mid-twentieth century, yet their precise timing, dosing, and duration in the setting of endovascular neurosurgery had never been systematically examined in a large prospective cohort. The SESIA investigators demonstrated that a rigorous observational analysis can identify a signal strong enough to justify randomized testing, potentially accelerating the path to improved patient outcomes without waiting for the decade-long development cycle of a new drug. For patients facing flow diverter therapy for an unruptured brain aneurysm, the prospect of a simple, cheap, and short steroid course that could cut the risk of disabling stroke by more than half is a finding that deserves the attention of every neurosurgeon, neurologist, and intensivist who cares for these patients.

Subject of Research: Low-Dose Glucocorticoids Adjunctive to Flow Diverter Therapy for Unruptured Intracranial Aneurysms Improve Cerebrovascular Outcomes

Article Title: Low-Dose Glucocorticoids Adjunctive to Flow Diverter Therapy for Unruptured Intracranial Aneurysms Improve Cerebrovascular Outcomes

Article References: Wen, Z., Chen, X., Tong, X., Huang, C., Huang, M., Lin, J., Xu, A., Yang, H., Zhang, X., Lin, Y., Huang, J., Ge, R., Yuan, H., Peng, C., Liu, Y., Jin, F., Su, S., Zhang, X., Li, X., … Feng, X. (2026). Low-Dose Glucocorticoids Adjunctive to Flow Diverter Therapy for Unruptured Intracranial Aneurysms Improve Cerebrovascular Outcomes. Nature Communications. https://doi.org/10.1038/s41467-026-78408-w

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78408-w

Keywords: Low-Dose, Glucocorticoids, Adjunctive, Flow, Diverter, Therapy, Unruptured, Intracranial, Aneurysms, Improve, Cerebrovascular, Outcomes